Prevention of cancer chemotherapy-induced renal impairment

Prevention of cancer chemotherapy-induced renal impairment refers to clinical strategies and cytoprotective therapies aimed at mitigating drug-induced nephrotoxicity in oncology patients receiving cytotoxic antineoplastic agents Cytotoxic regimens—most notably platinum compounds, alkylating agents, and antimetabolites—frequently damage the renal tubules, vasculature, and glomeruli through mechanisms such as oxidative stress, acute tubular necrosis, direct cellular apoptosis, and intratubular cry...

Prevention of cancer chemotherapy-induced renal impairment refers to clinical strategies and cytoprotective therapies aimed at mitigating drug-induced nephrotoxicity in oncology patients receiving cytotoxic antineoplastic agents Prophylaxis in this setting is designed to maintain renal perfusion, reduce toxic intrarenal drug accumulation, and prevent severe acute kidney injury, thereby avoiding treatment interruptions or irreversible loss of kidney function

Cytotoxic regimens—most notably platinum compounds, alkylating agents, and antimetabolites—frequently damage the renal tubules, vasculature, and glomeruli through mechanisms such as oxidative stress, acute tubular necrosis, direct cellular apoptosis, and intratubular crystal precipitation

Cytotoxic regimens—most notably platinum compounds, alkylating agents, and antimetabolites—frequently damage the renal tubules, vasculature, and glomeruli through mechanisms such as oxidative stress, acute tubular necrosis, direct cellular apoptosis, and intratubular crystal precipitation

Clinically, this impairment manifests as an acute or progressive decline in glomerular filtration rate, abrupt elevations in serum creatinine and blood urea nitrogen, proteinuria, and severe electrolyte derangements

Clinically, this impairment manifests as an acute or progressive decline in glomerular filtration rate, abrupt elevations in serum creatinine and blood urea nitrogen, proteinuria, and severe electrolyte derangements

Prophylaxis in this setting is designed to maintain renal perfusion, reduce toxic intrarenal drug accumulation, and prevent severe acute kidney injury, thereby avoiding treatment interruptions or irreversible loss of kidney function